背景:膀胱癌是泌尿系统最常见的恶性肿瘤,寻找新的可靠的生物标志物对膀胱癌的个体化治疗具有重要的临床意义。本研究旨在探讨核增殖抗原(Ki-67)或Profilin-1(PFN1)水平之间的相关性。临床病理特征,膀胱癌患者的术后预后。
方法:在苏州大学附属第四医院行经尿道膀胱肿瘤电切术的膀胱癌患者,选择2019年1月至2021年1月的医院作为研究组(n=60),选取同期膀胱癌良性病变患者60例作为对照组。分析两组患者肿瘤及膀胱组织中Ki-67和PFN1的表达情况。Ki-67记录患者的病理参数并计算患者的术后预后。Ki-67与PFN1表达水平的相关性,病理参数,并对术后预后进行分析。
结果:研究组中Ki-67和PFN1的阳性表达率分别为63.33%和73.33%,分别,显著高于对照组的阳性表达率(χ2=14.803、17.757,p<0.001)。Ki-67和PFN1的阳性表达率与组织学分级有关。临床分期,渗透,淋巴结转移,差异均有统计学意义(p<0.05)。非肌肉浸润性膀胱癌(NMIBC)的膀胱癌患者,高级组织学分级,Ta~T1临床分期,侵入性,和淋巴结转移患者的Ki-67阳性表达率高于肌层浸润性膀胱癌(MIBC),低级组织学分级,T2~T4,非侵入性,无淋巴结转移.Ki-67的高表达与性别无关,年龄,肿瘤直径,血管侵犯(p>0.05)。Ki-67阳性表达组的生存时间和3年生存率明显低于Ki-67阴性表达组(p<0.05)。PFN1阳性表达组的生存时间和3年生存率明显低于PFN1阴性表达组(p<0.05)。
结论:Ki-67和PFN1在膀胱肿瘤组织中的阳性表达率明显高于膀胱组织。和病理模式,组织学分级,临床分期,渗透,Ki-67和PFN1的阳性表达率与淋巴结转移有关,年龄,肿瘤直径和血管侵犯与Ki-67和PFN1的阳性表达率无关。Ki-67阳性和PFN1阳性表达的膀胱癌患者的生存时间和3年生存率较短。
BACKGROUND: Bladder cancer is the most common malignancy of the urinary system, and the search for new and reliable biomarkers has important clinical significance for the personalized treatment of bladder cancer. This study aims to explore the correlation between nuclear proliferation antigen (Ki-67) or Profilin-1 (PFN1) levels, clinicopathological characteristics, and postoperative prognosis in patients with bladder cancer.
METHODS: Patients with bladder cancer who underwent transurethral resection of bladder cancer tumor in The Fourth Affiliated Hospital of Soochow University, hospital from January 2019 to January 2021 were selected as the study group (n = 60), and patients with benign lesions of bladder cancer during the same period were selected as the control group (n = 60). The expression of Ki-67 and PFN1 in tumor and bladder tissues of the two groups was analyzed. Ki-67 recorded the patient\'s pathological parameters and calculated the patient\'s postoperative prognosis. The correlation between Ki-67 and PFN1 expression levels, pathological parameters, and postoperative prognosis was analyzed.
RESULTS: The positive expression rates of Ki-67 and PFN1 in the study group were 63.33% and 73.33%, respectively, which were significantly higher than the positive expression rates in the control group (χ2 = 14.803, 17.757, p < 0.001). The positive expression rates of Ki-67 and PFN1 were related to histological grade, clinical stage, infiltration, and lymph node metastasis, and the differences were statistically significant (p < 0.05). Bladder cancer patients with non muscle-invasive bladder cancer (NMIBC), high-grade histological grade, Ta~T1 clinical stage, invasive, and lymph node metastasis have a higher Ki-67 positive expression rate than bladder cancer patients with muscle-invasive bladder cancer (MIBC), low-grade histological grade, T2~T4, non-invasive, and no lymph node metastasis. The high expression level of Ki-67 has little relationship with gender, age, tumor diameter, and vascular invasion (p > 0.05). The survival time and three-year survival rate of the Ki-67 positive expression group were significantly lower than those of the Ki-67 negative expression group (p < 0.05). The survival time and three-year survival rate of the PFN1 positive expression group were significantly lower than those of the PFN1 negative expression group (p < 0.05).
CONCLUSIONS: The positive expression rates of Ki-67 and PFN1 in bladder tumor tissue are significantly higher than those in bladder tissue, and pathological pattern, histological grade, clinical stage, infiltration, and lymph node metastasis are related to the positive expression rates of Ki-67 and PFN1, and different genders, ages, tumors diameter and vascular invasion are not related to the positive expression rates of Ki-67 and PFN1. The survival time and three-year survival rates of bladder cancer patients with Ki-67 positive and PFN1 positive expression are shorter.